

# 2020/21 Financial Performance

Author: Chris Powell – Interim Head of Financial Planning & Analysis

Sponsor: Simon Lazarus - Interim Chief Financial Officer

Trust Board paper I4

## Purpose of Report:

This paper is for:	Description	Select (X)
Decision	To formally receive a report and approve its recommendations OR a particular course of action	
Discussion	To discuss, in depth, a report noting its implications without formally approving a recommendation or action	X
Assurance	To assure the Board that systems and processes are in place, or to advise a gap along with treatment plan	
Noting	For noting without the need for discussion	

## Previous Consideration:

Meeting	Date	Please clarify the purpose of the paper to that meeting using the categories above
CMG Board (specify which CMG)		
Executive Performance Board	26.10.20	Discussion
Trust Board Committee		
Trust Board		

## Executive Summary

This paper updates the Trust Board on the financial performance of the Trust at Month 6 of 2020/21.

To support Trusts during the COVID-19 crisis, the NHS is providing Top Up funding via NHSE&I. This consists of an upfront Top Up payment that is an estimate of the additional funding required by an individual Trust to meet their breakeven duty from April 2020 to September 2020 and is based on each Trust's underlying financial position, and a retrospective adjustment in line with the actual in year reported financial position.

The Month 6 report shows actual financial performance including the impact of COVID-19 and the position excluding COVID-19 expenditure and the reduction in income due to COVID-19.

As draft operational plans were submitted to NHSE&I in March 2020, and consistent with the basis of the calculation of the Top Up payment, planned income and expenditure for the Trust in the monthly NHSE&I monitoring return is as calculated by NHSE&I. Whilst this

does not impact upon the reporting of actuals, it does mean that the variance to plan reported externally is different to the variance to plan reported internally by the Trust against its interim budget.

The Trust set interim budgets for Months 1 to 6 of 2020/21, in order to establish control totals based on existing income and expenditure levels. These interim budgets are the basis for the Trust's planned performance for internal reporting purposes for Months 1-6. The Trust's financial plan for the second half of the financial year in accordance with Phase 3 Guidance was approved at the extraordinary Trust Board meeting on 21<sup>st</sup> October 2020.

## Questions:

### 1. What is the financial performance for the period ending 30<sup>th</sup> September 2020?

The actual position including Top Up funding of £59.4m is breakeven. The financial position excluding Top Up funding is a deficit of £59.4m, which is £2.9m favourable to plan.

### 2. What are the main issues to note in the Month 6 financial performance

The main issues are as follows:

- Breakeven has been achieved as a result of Top Up income
- Excluding Top Up income, reported performance is a £59.4m deficit, £2.9m favourable to plan
- Patient care income is £0.9m below plan at Month 6, reflecting a work in progress adjustment in month
- Under recovery of other income is likely to continue in future months due to the impact of COVID-19

### 3. What are the risks to financial performance in the remainder of the year

- Cost improvement plans need to be finalised and implemented to deliver savings and reduce the Trust's underlying deficit
- The scale and duration of the impact of COVID-19 on patient activity, income and expenditure is uncertain and will require ongoing refinement to forecasting of financial performance throughout the year aligned to restoration and recovery.

## Input Sought:

The Trust Board is asked to:

- **Note** the 2020/21 Month 6 reported financial position and the impact of Top Up funding
- **Note** the risks due to COVID-19 to financial forecasting and financial performance for the remainder of the year

## For Reference:

This report relates to the following UHL quality and supporting priorities:

### 1. Quality priorities

Safe, surgery and procedures  
Safely and timely discharge  
Improved Cancer pathways  
Streamlined emergency care  
Better care pathways  
Ward accreditation

Not applicable  
Not applicable  
Not applicable  
Not applicable  
Not applicable  
Not applicable

### 2. Supporting priorities

People strategy implementation  
Estate investment and reconfiguration  
e-Hospital  
More embedded research  
Better corporate services  
Quality strategy development

Not applicable  
Not applicable  
Not applicable  
Not applicable  
Not applicable  
Not applicable

### 3. Equality Impact Assessment and Patient and Public Involvement considerations:

- What was the outcome of your Equality Impact Assessment (EIA)? **Not applicable**
- Briefly describe the Patient and Public Involvement (PPI) activities undertaken in relation to this report, or confirm that none were required. **None required**
- How did the outcome of the EIA influence your Patient and Public Involvement? **Not applicable**
- If an EIA was not carried out, what was the rationale for this decision? **Not applicable**

### 4. Risk and Assurance

Risk Reference:

Does this paper reference a risk event?	Select (X)	Risk Description:
<b>Strategic:</b> Does this link to a <b>Principal Risk</b> on the BAF?	X	Principal Risk 4 – Financial Sustainability
<b>Organisational:</b> Does this link to an <b>Operational/Corporate Risk</b> on Datix Register		
<b>New Risk</b> identified in paper: What <b>type</b> and <b>description</b> ?		
<b>None</b>		

5. Scheduled date for the **next paper** on this topic: 3<sup>rd</sup> December 2020

6. Executive Summaries should not exceed **5 sides** [My paper does/~~does not~~ comply]

# Contents

---

<b>Executive Summary</b>	<a href="#">Page 2</a>
<b>I&amp;E: Overall Position</b>	
• September 2020: Key Facts	<a href="#">Page 3</a>
• Financial Performance	<a href="#">Page 4</a>
• Financial Performance: Covid 19	<a href="#">Page 5</a>
• Performance by CMG and Directorate: Year to Date	<a href="#">Page 6</a>
• <b>Assets &amp; Liabilities</b>	
• Cash	<a href="#">Page 7</a>
• Liquidity	<a href="#">Page 8</a>
• BPCC	<a href="#">Page 9</a>
• Capital	<a href="#">Page 10</a>
• Statement of Financial Position	<a href="#">Page 11</a>
<b>Appendix 1: CMG Performance</b>	
• CHUGGS & CSI	<a href="#">Page 12</a>
• ESM & ITAPS	<a href="#">Page 13</a>
• MSS & RRCV	<a href="#">Page 14</a>
• W&C & R&I	<a href="#">Page 15</a>
• Estates & Corporate	<a href="#">Page 16</a>
• Alliance	<a href="#">Page 17</a>
<b>Appendix 2: Pay Analysis</b>	<a href="#">Page 18</a>
<b>Appendix 3: WTE Analysis</b>	<a href="#">Page 19</a>

# Executive Summary

## Financial performance

### Financial Performance

- Deficit of £59.4m, £2.9m favourable to the Trust's interim plan, reflecting the impact of Covid-19 expenditure (£20.9m) and a reduction in income (£7.2m) due to Covid-19, offset by reduced income and expenditure due to lower activity of £30.9m.
- After Top Up income (£59.4m): Break-even.

### Main areas of variance YTD

- **Patient Care Income (PCI), £0.9mA to Plan:** primarily due the impact of work in progress at the end of the month (£1.2m)
- **Other income, £10.1A to plan:** reflecting the impact of Covid-19 (£6.1m).
- **Top Up income £59.4mF:** This is additional income provided to all Trusts to achieve breakeven on income and expenditure.
- **Total Pay Costs: £362.6m, £3.2mA** reflecting Covid-19 expenditure of £8.9m offset by lower underlying expenditure of £5.8m.
- **Non-Pay: £192.2m, £16.3mF** The Trust retains a favourable non pay position following a £7m increase in total spend from the prior month. This increase was seen in excluded drugs costs £3.3m, activity related consumables and testing costs £3.3m and equipment lease costs £0.7m .
- The favourable variance against plan is due to reflecting significant underspends in MSS £5.6m, RRCV £2.9m and CHUGGS £2.7m resulting from reduced activity as a consequence of Covid-19.

## Cash

### Cash Bridge:

- Closing cash balance of £122.6m.
- We have achieved a YTD breakeven position; and have funded £21.1m of capital expenditure.
- The closing cash balance includes £97.1m of payments that have been received in advance (reflecting the revised treatment of R&D income in the 2019/20 accounts), and the underlying cash position excluding these payments is £25.5m.


## Capital

- The Trust's total capital spend at September was £21.1m.

### Key

F refers to a Favourable variance to plan, A refers to an Adverse variance to plan

# September 2020: Key Facts



- Key**
- EBITDA refers to Earnings Before Interest, Taxes, Depreciation and Amortisation
  - Colour indicates status of variance on planned position (Green is Favourable/In Line and Red is Adverse)
  - Number relates to variance YTD

# Financial Performance: Break even after £59.4m Top Up income

	Sep-20			YTD		
	Plan	Actual	Variance	Plan	Actual	Variance
	£'000	£'000	£'000	£'000	£'000	£'000
Patient Care Income	77,755	76,203	(1,552)	466,530	465,605	(924)
Non Patient Care Income	300	425	125	2,062	1,102	(960)
Other Operating Income	10,059	7,735	(2,324)	60,562	51,376	(9,186)
<b>Total Income</b>	<b>88,114</b>	<b>84,363</b>	<b>(3,750)</b>	<b>529,153</b>	<b>518,083</b>	<b>(11,070)</b>
Pay Costs	(58,511)	(59,745)	(1,234)	(350,599)	(351,982)	(1,383)
Pay Costs: Agency	(1,318)	(1,747)	(429)	(8,819)	(10,598)	(1,779)
Non Pay	(35,056)	(38,022)	(2,966)	(208,500)	(192,185)	16,315
<b>Total Operating Costs</b>	<b>(94,885)</b>	<b>(99,514)</b>	<b>(4,629)</b>	<b>(567,918)</b>	<b>(554,765)</b>	<b>13,153</b>
<b>EBITDA</b>	<b>(6,771)</b>	<b>(15,151)</b>	<b>(8,380)</b>	<b>(38,764)</b>	<b>(36,681)</b>	<b>2,083</b>
<b>Non Operating Costs</b>	<b>(3,932)</b>	<b>(4,412)</b>	<b>(480)</b>	<b>(23,593)</b>	<b>(23,034)</b>	<b>559</b>
<b>Surplus / (Deficit)</b>	<b>(10,703)</b>	<b>(19,563)</b>	<b>(8,860)</b>	<b>(62,357)</b>	<b>(59,715)</b>	<b>2,642</b>
Adjustments for Donated Assets	14	62	48	87	304	217
<b>Underlying Surplus/(Deficit)</b>	<b>(10,689)</b>	<b>(19,501)</b>	<b>(8,812)</b>	<b>(62,270)</b>	<b>(59,411)</b>	<b>2,859</b>
Net Top up Income		19,501	19,501	0	59,411	59,411
<b>Actual Surplus / (Deficit)</b>	<b>(10,689)</b>	<b>0</b>	<b>10,689</b>	<b>(62,270)</b>	<b>0</b>	<b>62,270</b>

I & E £'000

**NHS Patient Care Income: £465.6m, £0.9mA** primarily due to a work in progress value of £1.2m.

**Other Income : £52.5m, £10.1mA to plan** reflecting the impact of Covid-19, with significant variances reported in Facilities, due to £4.1m loss of income from car parking, and catering, and R&D (£1.7m) due to lower research income.

**Total Pay Costs: £362.6m, £3.2A.** After adjusting for the impact of Covid-19, the Trust is reporting a £5.8m favourable pay position, reflecting vacancies.

**Non-Pay: £192.2m, £16.3mF,** The Trust retains a favourable non pay position following a £7m increase in total spend from the prior month. This increase was seen in excluded drugs costs £3.3m, activity related consumables and testing costs £3.3m and equipment lease costs £0.7m. The favourable variance to plan reflects significant underspends in MSS £5.6m, RRCV £2.9m and CHUGGS £2.7m resulting from reduced activity as a consequence of Covid-19.

**EBITDA: deficit of £36.7m, £2.1mF**

- **Non-Operating Costs: £23m, £0.6mF,** reflecting lower than depreciation than planned, due to the timing of capital expenditure.
- **Top Up funding: The Trust's deficit at month 6 is £59.4m.** After the receipt of national Top Up income of £59.4m a breakeven position is reported.

## Key

- EBITDA refers to Earnings Before Interest, Taxes, Depreciation and Amortisation
- F refers to a Favourable variance to plan
- A refers to an Adverse variance to plan



# Financial Performance: Covid-19

	Sep-20 COVID Impact £'000	YTD COVID Impact £'000	
I&E £'000	Patient Care Income	(1,241)	(1,055)
	Non Patient Care Income	(81)	(773)
	Other Operating Income	(774)	(5,354)
	<b>Total Income</b>	<b>(2,095)</b>	<b>(7,182)</b>
	Pay Costs	(328)	(7,521)
	Pay Costs: Agency	178	(1,395)
	Non Pay	(606)	(11,967)
	<b>Total Operating Costs</b>	<b>(756)</b>	<b>(20,883)</b>
	<b>EBITDA</b>	<b>(2,851)</b>	<b>(28,065)</b>
	<b>Surplus / (Deficit)</b>	<b>(2,851)</b>	<b>(28,065)</b>
	Covid -19 Top Up	2,851	28,065
<b>Actual Surplus / (Deficit)</b>	<b>0</b>	<b>0</b>	

## Activity Performance

Activity Type	YTD (19/20) Activity	YTD (20/21) Activity	Difference Activity	Difference %
Day Case	54,481	29,632	(24,849)	-46%
Elective Inpatient	9,977	5,272	(4,705)	-47%
Emergency / Non-elective Inpatient	59,952	49,337	(10,615)	-18%
Emergency Department	130,350	83,339	(47,011)	-36%
Outpatient	509,040	395,534	(113,506)	-22%
Critical Care Services	29,640	23,342	(6,298)	-21%
Renal Dialysis and Transplant	94,326	97,154	2,828	3%
Other Activity	4,309,072	2,555,338	(1,753,734)	-41%

### Key

- EBITDA refers to Earnings Before Interest, Taxes, Depreciation and Amortisation

**Patient Care Income: £1.1m YTD**, reflecting the reduction on the Trust's work in progress adjustment (WIP), which estimates the value of activity not yet discharged from hospital compared to the previous year end.

**Other Income: £6.1m YTD**, reflecting the impact reported in Facilities, due to £4.1m loss of income from car parking, catering and shuttle bus, R&D £0.7m due to lower research income and CSI £1.0m reflecting lower pathology income.

**Total Pay and Agency Costs: £8.9m YTD**, predominantly relating to medical, nursing and additional Covid-19 support staff. The CMGs in the main this relate to include ESM £1.4m, ITAPS £1.3m, Trust wide workforce support £3.6m, RRCV £0.5m and Estates & Facilities £0.8m. The £0.2m in month reduction to agency expenditure relates to ESM reclassifying Covid-19 spend.

**Non-Pay: £12m YTD**, relating to PPE, consumable, cleaning supplies, Covid-19 testing kits, Trust signage etc. These CMGs include, CSI £3m, ITAPS £2.7m, Trust wide supplies £2m, Estates and Facilities £2.2m, ESM £0.5m and W&C £0.4m.

**Covid-19 top up funding.** As a result of the interim financial arrangements in place during Covid-19, all NHS providers are paid a block payment from commissioners at values set nationally by NHSE&I. After the receipt of national top up income a breakeven position is reported.

## Activity Performance

Although income is blocked, the Trust is reporting significant reductions in activity due to Covid-19. The table shows September year to date activity compared to the same period of last financial year, as an indication of the impact of Covid-19 on activity.

Elective services such as day case, elective inpatient and outpatients have been impacted most significantly, with emergency inpatients and critical care impacted to a lesser degree. Renal Dialysis and Transplant is the only service with activity higher than last year's performance. GP direct access and screening services have seen significant reductions compared to the same period last year, these are included in Other Activity.

# Performance by CMG and Directorates: Year to Date

	CHUGGS			
	Plan	YTD	COVID Impact	YTD - Underlying Variance
	£'m	£'m	£'m	£'m
PCI	89.1	89.1	0.0	(0.0)
Other Income	4.2	4.0	0.0	(0.1)
<b>Total Income</b>	<b>93.3</b>	<b>93.1</b>	<b>0.0</b>	<b>(0.1)</b>
Total Pay	(33.0)	(32.3)	0.2	0.9
Total Non-Pay	(33.3)	(30.6)	0.0	2.8
<b>EBITDA</b>	<b>27.0</b>	<b>30.2</b>	<b>0.2</b>	<b>3.5</b>

	CSI			
	Plan	YTD	COVID Impact	YTD - Underlying Variance
	£'m	£'m	£'m	£'m
PCI	23.3	23.3	0.0	(0.0)
Other Income	5.7	5.3	(1.1)	0.7
<b>Total Income</b>	<b>29.0</b>	<b>28.6</b>	<b>(1.1)</b>	<b>0.7</b>
Total Pay	(49.1)	(48.6)	0.4	0.9
Total Non-Pay	(5.3)	(4.8)	3.0	3.4
<b>EBITDA</b>	<b>(25.4)</b>	<b>(24.8)</b>	<b>4.4</b>	<b>5.0</b>

	ESM			
	Plan	YTD	COVID Impact	YTD - Underlying Variance
	£'m	£'m	£'m	£'m
PCI	100.1	100.1	0.0	(0.0)
Other Income	4.9	4.2	0.0	(0.8)
<b>Total Income</b>	<b>105.0</b>	<b>104.3</b>	<b>0.0</b>	<b>(0.8)</b>
Total Pay	(59.7)	(62.5)	1.4	(1.4)
Total Non-Pay	(27.1)	(25.9)	0.5	1.8
<b>EBITDA</b>	<b>18.2</b>	<b>15.9</b>	<b>1.9</b>	<b>(0.4)</b>

	ITAPS			
	Plan	YTD	COVID Impact	YTD - Underlying Variance
	£'m	£'m	£'m	£'m
PCI	18.4	18.4		0.0
Other Income	1.9	1.8	(0.0)	(0.0)
<b>Total Income</b>	<b>20.3</b>	<b>20.3</b>	<b>(0.0)</b>	<b>(0.0)</b>
Total Pay	(37.7)	(38.4)	1.3	0.6
Total Non-Pay	(12.3)	(11.8)	2.7	3.2
<b>EBITDA</b>	<b>(29.7)</b>	<b>(29.9)</b>	<b>4.0</b>	<b>3.8</b>

	MSS			
	Plan	YTD	COVID Impact	YTD - Underlying Variance
	£'m	£'m	£'m	£'m
PCI	58.1	58.1	0.0	(0.0)
Other Income	2.5	2.1	0.0	(0.4)
<b>Total Income</b>	<b>60.6</b>	<b>60.2</b>	<b>0.0</b>	<b>(0.4)</b>
Total Pay	(30.4)	(28.7)	0.4	2.1
Total Non-Pay	(14.8)	(9.2)	0.3	5.9
<b>EBITDA</b>	<b>15.3</b>	<b>22.3</b>	<b>0.7</b>	<b>7.6</b>

	RRCV			
	Plan	YTD	COVID Impact	YTD - Underlying Variance
	£'m	£'m	£'m	£'m
PCI	101.2	101.2	0.0	0.0
Other Income	3.6	2.7	(0.6)	(0.2)
<b>Total Income</b>	<b>104.8</b>	<b>103.9</b>	<b>(0.6)</b>	<b>(0.2)</b>
Total Pay	(44.8)	(44.3)	0.5	1.1
Total Non-Pay	(33.2)	(30.3)	0.3	3.2
<b>EBITDA</b>	<b>26.7</b>	<b>29.3</b>	<b>1.4</b>	<b>4.0</b>


	W&C			
	Plan	YTD	COVID Impact	YTD - Underlying Variance
	£'m	£'m	£'m	£'m
PCI	87.2	87.2	0.0	(0.0)
Other Income	4.4	3.6	0.0	(0.8)
<b>Total Income</b>	<b>91.5</b>	<b>90.7</b>	<b>0.0</b>	<b>(0.8)</b>
Total Pay	(47.6)	(47.8)	0.2	(0.1)
Total Non-Pay	(20.2)	(18.6)	0.4	2.1
<b>EBITDA</b>	<b>23.7</b>	<b>24.4</b>	<b>0.6</b>	<b>1.3</b>

	ESTATES			
	Plan	YTD	COVID Impact	YTD - Underlying Variance
	£'m	£'m	£'m	£'m
PCI	0.0	0.0	0.0	0.0
Other Income	11.0	6.9	(4.1)	0.1
<b>Total Income</b>	<b>11.0</b>	<b>6.9</b>	<b>(4.1)</b>	<b>0.1</b>
Total Pay	(19.4)	(20.2)	0.8	(0.0)
Total Non-Pay	(19.7)	(18.8)	2.2	3.1
<b>EBITDA</b>	<b>(28.1)</b>	<b>(32.0)</b>	<b>7.1</b>	<b>3.2</b>

	CORPORATE			
	Plan	YTD	COVID Impact	YTD - Underlying Variance
	£'m	£'m	£'m	£'m
PCI	0.0	0.0	0.0	0.0
Other Income	3.5	3.1	0.0	(0.4)
<b>Total Income</b>	<b>3.5</b>	<b>3.1</b>	<b>0.0</b>	<b>(0.4)</b>
Total Pay	(19.5)	(19.1)	0.0	0.4
Total Non-Pay	(23.7)	(23.9)	0.5	0.3
<b>EBITDA</b>	<b>(39.7)</b>	<b>(39.9)</b>	<b>0.5</b>	<b>0.3</b>

# September 2020: Cash movement

Year to Date Cash Bridge £'000




## Cash Bridge:

- Closing cash balance of £122.6m.
- We have achieved a YTD breakeven position; and have funded £20.3m of capital expenditure from internal sources. Additional capital funding of £0.8m has been received. The Trust's cash position remains higher than planned due to current funding arrangements where we continue to receive monthly cash in advance.

## Daily Cash Balance

- In line with forecast, the mid-month peak is driven by receipt of SLA income and reduction on 25<sup>th</sup> of due to the monthly payroll run.

Daily Cash Balance – September 2020



# Liquidity as at 30 September 2020

	Liquidity			Ageing				Total	
	Opening	YTD	Movement	0 - 30 Days	31 - 60 Days	61 - 90 Days	Over 90 Days	Over 90 Days	
	£'000	£'000	£'000	£'000	£'000	£'000	£'000	%	
<b>Accounts Receivable</b>	NHS receivables - revenue	26,756	16,023	(10,733)	12,248	1,905	414	1,456	9%
	Non-NHS receivables - revenue	19,057	7,799	(11,258)	3,386	663	217	3,533	45%
	Provision for the impairment of receivables	(3,072)	(3,652)	(580)	(3,652)				
	Non-NHS prepayments and accrued income	8,399	13,957	5,558	13,957				
	VAT	1,715	3,326	1,611	3,326				
	Other receivables	332	31	(301)	31				
	<b>TOTAL</b>	<b>53,187</b>	<b>37,484</b>	<b>(15,703)</b>	<b>29,296</b>	<b>2,568</b>	<b>631</b>	<b>4,989</b>	
<b>Accounts Payable</b>	NHS payables - revenue	(13,959)	(9,627)	4,332	(2,895)	(1,114)	(978)	(4,640)	48%
	Non-NHS payables - revenue	(15,727)	(23,966)	(8,239)	(19,906)	(1,881)	(626)	(1,553)	6%
	Non-NHS payables - capital	(3,132)	(1,592)	1,540	(1,322)	(125)	(42)	(103)	6%
	Non-NHS accruals and deferred income	(26,626)	(1)	26,625	(1)				
	Social security costs	(7,571)	(8,062)	(491)	(8,062)				
	Tax	(6,173)	(7,108)	(935)	(7,108)				
	Other	(14,851)	(15,253)	(402)	(15,253)				
	Payments received on account	(12,991)	(97,141)	(84,150)	(97,141)				
	<b>TOTAL</b>	<b>(101,030)</b>	<b>(162,750)</b>	<b>(61,720)</b>	<b>(151,688)</b>	<b>(3,120)</b>	<b>(1,646)</b>	<b>(6,296)</b>	
<b>Total Liquidity</b>	<b>(47,843)</b>	<b>(125,266)</b>	<b>(77,423)</b>						

**Liquidity:** movement of £77.4m from the opening position due to:

- Accounts receivable: decrease £15.7m
- Accounts payable: increase of £61.7m

**Ageing:** NHSI target of 5% or less within over 90 days, key areas of under-performance:

- NHS receivables: 9% - £1.5m over 90 days
- Non-NHS receivables: 45% - £3.5m over 90 days
- NHS payables-revenue: 48% - £4.6m over 90 days
- Non- NHS payables-revenue: 6% - £1.6m over 90 days

# YTD Better Payments Practice Code: Non- compliant

## BPPC Performance

Better Payment Practice Code - Measure of Compliance	September YTD		Prior Month YTD	
	Number	£000s	Number	£000s
<b>All</b>				
Total Invoices Paid in the Year	76,229	381,202	60,688	341,656
Total Invoices Paid Within Target	68,972	350,069	56,228	312,967
<b>Percentage of Invoices Paid Within Target</b>	<b>90.5%</b>	<b>91.8%</b>	<b>92.7%</b>	<b>91.6%</b>
<b>Non-NHS Payables</b>				
Total Non-NHS Invoices Paid in the Year	✔ 73,657	320,940	58,391	291,203
Total Non-NHS Invoices Paid Within Target	✔ 67,558	300,457	55,062	272,857
<b>Percentage Invoices Paid Within Target</b>	<b>91.7%</b>	<b>93.6%</b>	<b>94.3%</b>	<b>93.7%</b>
<b>NHS Payables</b>				
Total Invoices Paid in the Year	✔ 2,572	60,262	2,297	50,453
Total Invoices Paid Within Target	✔ 1,414	49,612	1,166	40,110
<b>Percentage of Invoices Paid Within Target</b>	<b>55.0%</b>	<b>82.3%</b>	<b>50.8%</b>	<b>79.5%</b>

Overall compliance is 91% by volume and 92% value which is consistent with the previous month. The Trust has achieved 92% compliance against the 95% target by volume for non-NHS suppliers in the YTD.

## Capital: September £21.1m YTD spend

---

Scheme Name	YTD Plan	YTD Actual	YTD Variance
Pre-commitments	6,788	4,164	(2,624)
ICU	7,290	5,965	(1,325)
Estates and Facilities Schemes	5,793	3,024	(2,769)
IT Schemes	2,225	1,396	(829)
Business cases and Reconfiguration Schemes	2,188	934	(1,254)
Medical Equipment Schemes	4,688	391	(4,297)
Covid - 19 capital expenditure	5,225	4,376	(849)
Other Corporate / Other Schemes	1,109	829	(280)
<b>Total capital spend YTD</b>	<b>35,306</b>	<b>21,079</b>	<b>(14,227)</b>

- The Trust has spent £21.1m on capital expenditure against a year to date plan of £35.3m. The £14.2m variance reflects the requirement to review the phasing of expenditure commitments. This work is being led by the Head of Finance (Capital and Cash), and is being overseen by the Financial Improvement Group.
- Expenditure includes £4.4m on Covid-19 related equipment and projects.

# September 2020: Statement of Financial Position

	Aug-20 £000's Actual	Sep-20 £000's Actual	Movement £000's Actual
<b>Non Current Assets</b>			
Property, plant and equipment	534,043	535,892	1,849
Intangible assets	5,682	5,505	(177)
Trade and other receivables	3,757	2,019	(1,738)
<b>TOTAL NON CURRENT ASSETS</b>	<b>543,482</b>	<b>543,416</b>	<b>(67)</b>
<b>Current Assets</b>			
Inventories	21,365	21,364	(1)
Trade and other receivables	28,982	35,728	6,746
Cash and cash equivalents	122,464	122,561	97
<b>TOTAL CURRENT ASSETS</b>	<b>172,811</b>	<b>179,654</b>	<b>6,843</b>
<b>Current Liabilities</b>			
Trade and other payables	(52,794)	(55,860)	(3,066)
NHS Accruals and Deferred Income	(102,416)	(97,142)	5,274
Dividend payable	(4,990)	(6,354)	(1,364)
Borrowings / Finance Leases	(3,063)	(2,285)	778
Other Liabilities	(27,707)	(29,366)	(1,660)
Provisions for liabilities and charges	(6,709)	(6,709)	0
<b>TOTAL CURRENT LIABILITIES</b>	<b>(197,678)</b>	<b>(197,716)</b>	<b>(38)</b>
<b>NET CURRENT ASSETS (LIABILITIES)</b>	<b>(24,868)</b>	<b>(18,062)</b>	<b>6,805</b>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>	<b>518,615</b>	<b>525,354</b>	<b>6,739</b>
<b>Non Current Liabilities</b>			
Borrowings / Finance Leases	(1,192)	(5,662)	(4,470)
Provisions for liabilities and charges	(6,126)	(6,045)	81
<b>TOTAL NON CURRENT LIABILITIES</b>	<b>(7,318)</b>	<b>(11,708)</b>	<b>(4,390)</b>
<b>TOTAL ASSETS EMPLOYED</b>	<b>511,297</b>	<b>513,646</b>	<b>2,349</b>
Public dividend capital	719,705	719,705	0
Revaluation reserve	168,557	168,342	(214)
Retained earnings	(376,965)	(374,402)	2,563
<b>TOTAL TAXPAYERS EQUITY</b>	<b>511,297</b>	<b>513,646</b>	<b>2,349</b>

Statement of Financial Position

- **Total Assets Employed:** Movement of £2.3m driven by prior year adjustments.
- **Working capital:**
  - Trade receivables have increased by £6.7m, mainly due to prior year audit adjustments now transacted.
  - Trade payables have increased by £3.1m.
- **Cash:**
  - The Trust's cash position remains higher than planned at £122.6m. This is driven by patient care income being received in advance from Commissioners.

# CMG Financial Performance (Appendix 1)

## CHUGGS

	Sep-20			YTD		
	Plan	Actual	Variance	Plan	Actual	Variance
	£'000	£'000	£'000	£'000	£'000	£'000
Patient Care Income	14,964	14,964	0	89,072	89,072	(0)
Non Patient Care Income	56	160	104	335	212	(123)
Other Operating Income	639	481	(158)	3,858	3,834	(25)
<b>Total Income</b>	<b>15,659</b>	<b>15,605</b>	<b>(54)</b>	<b>93,266</b>	<b>93,118</b>	<b>(148)</b>
Pay Costs	(5,294)	(5,373)	(79)	(31,721)	(31,343)	378
Pay Costs: Agency	(203)	(111)	92	(1,243)	(947)	296
Non Pay	(5,700)	(6,030)	(330)	(33,350)	(30,619)	2,731
<b>Total Operating Costs</b>	<b>(11,197)</b>	<b>(11,514)</b>	<b>(317)</b>	<b>(66,314)</b>	<b>(62,910)</b>	<b>3,404</b>
<b>Actual Surplus / (Deficit)</b>	<b>4,462</b>	<b>4,092</b>	<b>(370)</b>	<b>26,952</b>	<b>30,208</b>	<b>3,256</b>

## CHUGGS

**Patient Care Income:** Balanced position including a £22.8m block contract adjustment for under-performance against plan as a result of Covid.

**Other Income:** Under by £0.15m due to a drop in private patient activity and CEA income.

**Pay:** £0.7m favourable to plan, mainly due to limited use of WLI sessions (£0.4m) and vacancies across medical staff (£0.15m) and non-clinical staffing (£0.14m)

**Non Pay:** £2.7m favourable. Baseline drugs (£0.5m), non-use of Medinet in Endoscopy (£0.6m) and activity related savings consumables (£1.6m).

## CSI

	Sep-20			YTD		
	Plan	Actual	Variance	Plan	Actual	Variance
	£'000	£'000	£'000	£'000	£'000	£'000
Patient Care Income	3,797	3,797	0	23,328	23,328	(0)
Non Patient Care Income	35	9	(25)	207	111	(96)
Other Operating Income	910	851	(59)	5,457	5,200	(257)
<b>Total Income</b>	<b>4,741</b>	<b>4,657</b>	<b>(84)</b>	<b>28,992</b>	<b>28,639</b>	<b>(353)</b>
Pay Costs	(8,038)	(8,066)	(28)	(48,222)	(47,770)	452
Pay Costs: Agency	(146)	(164)	(18)	(890)	(871)	19
Non Pay	(863)	(719)	144	(5,264)	(4,801)	463
<b>Total Operating Costs</b>	<b>(9,047)</b>	<b>(8,949)</b>	<b>98</b>	<b>(54,376)</b>	<b>(53,441)</b>	<b>934</b>
<b>Actual Surplus / (Deficit)</b>	<b>(4,306)</b>	<b>(4,292)</b>	<b>14</b>	<b>(25,383)</b>	<b>(24,802)</b>	<b>581</b>

## CSI

**PCI:** Balanced position, due to block agreement as a result of the COVID19 settlement

**Other Income:** £0.3m adverse, inclusive of lost income due to COVID.

**Pay:** costs, including agency, £0.5m favourable. This includes £0.3m for COVID costs giving an underlying surplus of £0.8m. This reflects reduced premium pay linked to reduced activity.

**Non Pay:** Costs are £0.5m favourable to plan despite £0.3m increase in spend in month for covid related costs and increased activity testing.



# CMG Financial Performance

## ESM

	Sep-20			YTD		
	Plan	Actual	Variance	Plan	Actual	Variance
	£'000	£'000	£'000	£'000	£'000	£'000
Patient Care Income	17,045	17,045	(0)	100,092	100,092	(0)
Non Patient Care Income	22	(15)	(38)	134	(29)	(164)
Other Operating Income	801	481	(320)	4,804	4,197	(607)
<b>Total Income</b>	<b>17,868</b>	<b>17,510</b>	<b>(358)</b>	<b>105,031</b>	<b>104,260</b>	<b>(771)</b>
Pay Costs	(9,464)	(9,204)	261	(55,665)	(57,183)	(1,518)
Pay Costs: Agency	(540)	(971)	(430)	(4,081)	(5,314)	(1,233)
Non Pay	(4,444)	(5,761)	(1,317)	(27,105)	(25,877)	1,227
<b>Total Operating Costs</b>	<b>(14,449)</b>	<b>(15,935)</b>	<b>(1,486)</b>	<b>(86,850)</b>	<b>(88,374)</b>	<b>(1,524)</b>
<b>Actual Surplus / (Deficit)</b>	<b>3,419</b>	<b>1,575</b>	<b>(1,844)</b>	<b>18,181</b>	<b>15,886</b>	<b>(2,295)</b>

## ITAPS

	Sep-20			YTD		
	Plan	Actual	Variance	Plan	Actual	Variance
	£'000	£'000	£'000	£'000	£'000	£'000
Patient Care Income	2,881	2,881	(0)	18,432	18,432	0
Non Patient Care Income	4	3	(1)	22	8	(14)
Other Operating Income	307	278	(30)	1,844	1,814	(31)
<b>Total Income</b>	<b>3,192</b>	<b>3,161</b>	<b>(31)</b>	<b>20,298</b>	<b>20,254</b>	<b>(45)</b>
Pay Costs	(6,187)	(6,052)	135	(37,130)	(37,738)	(608)
Pay Costs: Agency	(93)	(118)	(26)	(565)	(638)	(73)
Non Pay	(2,015)	(2,085)	(71)	(12,290)	(11,771)	520
<b>Total Operating Costs</b>	<b>(8,294)</b>	<b>(8,256)</b>	<b>38</b>	<b>(49,985)</b>	<b>(50,147)</b>	<b>(161)</b>
<b>Actual Surplus / (Deficit)</b>	<b>(5,103)</b>	<b>(5,095)</b>	<b>8</b>	<b>(29,687)</b>	<b>(29,893)</b>	<b>(206)</b>

## ESM

**Patient Care Income:** In line with plan linked to the block arrangement. Under-performance across most points of delivery but largely within emergency pathway (ED and emergency inpatients).

**Other Income:** Teaching, Clinical Excellence Award, LDA and staff recharges are down against plan or within block, totalling £0.7m.

**Pay:** £2.8m adverse to plan. Excluding COVID a YTD deficit of £1.4m. Medical costs are overspent, offset by underspends in nursing.

**Non Pay:** £1.2m favourable to plan. Excluding COVID a YTD surplus of £1.8m. The YTD surplus has reduced by in month overspends on EDD clearing backlogs in processing of invoices (£1.9m). The balance of the underspend is due to a reduction in consumables linked to reduced activity and reduced demand for ambulances YTD.

## ITAPS

**Patient Care Income:** in line with plan linked to the block contract for M1-M6. Under-performance across most points of delivery except ECMO. Block related adjustment £1.1m Favourable.

**Other Income:** £45k adverse to plan. Under-performance of £14k due to private patient/overseas income and underperformance of £31k due to CEA award income.

**Pay:** £0.7m adverse to plan. Additional medical staff and nursing premium to cover ITU, of which £1.3m is Covid related. September has continued to see an increase in baseline WLI activity.

**Non Pay:** £0.5m favourable to plan despite £0.5m increase in spend in M6 (purchase of infusion pumps). Covid spend on consumables and supplies of £2.7m offsets the underspends on theatre related consumables.

# CMG Financial Performance

## MSS

	Sep-20			YTD			
	Plan	Actual	Variance	Plan	Actual	Variance	
	£'000	£'000	£'000	£'000	£'000	£'000	
I & E £'000	Patient Care Income	9,540	9,540	0	58,127	58,127	(0)
	Non Patient Care Income	12	3	(10)	73	6	(67)
	Other Operating Income	396	273	(123)	2,378	2,081	(297)
	<b>Total Income</b>	<b>9,948</b>	<b>9,816</b>	<b>(133)</b>	<b>60,578</b>	<b>60,215</b>	<b>(364)</b>
	Pay Costs	(4,935)	(4,678)	257	(29,606)	(27,870)	1,736
	Pay Costs: Agency	(132)	(110)	22	(803)	(807)	(5)
	Non Pay	(2,662)	(2,127)	534	(14,821)	(9,239)	5,583
	<b>Total Operating Costs</b>	<b>(7,728)</b>	<b>(6,915)</b>	<b>813</b>	<b>(45,230)</b>	<b>(37,916)</b>	<b>7,314</b>
	<b>Actual Surplus / (Deficit)</b>	<b>2,220</b>	<b>2,900</b>	<b>680</b>	<b>15,349</b>	<b>22,299</b>	<b>6,950</b>

## RRCV

	Sep-20			YTD			
	Plan	Actual	Variance	Plan	Actual	Variance	
	£'000	£'000	£'000	£'000	£'000	£'000	
I & E £'000	Patient Care Income	16,631	16,631	0	101,191	101,191	0
	Non Patient Care Income	131	159	28	751	264	(487)
	Other Operating Income	466	193	(273)	2,829	2,445	(385)
	<b>Total Income</b>	<b>17,228</b>	<b>16,983</b>	<b>(245)</b>	<b>104,771</b>	<b>103,899</b>	<b>(871)</b>
	Pay Costs	(7,284)	(7,239)	45	(44,143)	(43,317)	826
	Pay Costs: Agency	(115)	(117)	(1)	(704)	(964)	(260)
	Non Pay	(5,648)	(6,376)	(728)	(33,189)	(30,291)	2,898
	<b>Total Operating Costs</b>	<b>(13,048)</b>	<b>(13,732)</b>	<b>(685)</b>	<b>(78,035)</b>	<b>(74,572)</b>	<b>3,463</b>
	<b>Actual Surplus / (Deficit)</b>	<b>4,181</b>	<b>3,250</b>	<b>(930)</b>	<b>26,735</b>	<b>29,327</b>	<b>2,592</b>

## MSS

**Patient care income** in line with plan linked to the block arrangement. M6 YTD showed that MSS is operating on average between 55-60% capacity. The referral rate increased by 9% on last month however YTD its still 58% of last year.

**Pay spend** – 6% better than plan (£1.7m F). Key driver for this is vacancies within medical staffing, offset by the use of medical locums. Low WLI's for M6 as anticipated.

**Non Pay** relating to lower activity, 38% better than plan resulting in an underspend of £5.6m. The underspend is due to Drugs £1.5m and Clinical Supplies £3.5mF. Covid 19 related costs are £655k.

## RRCV

**Patient Care Income** in line with plan linked to the block arrangement. Under-performance across most points of delivery but largely within inpatient activity. Block related adjustment, £24.2m year to date.

**Other Income:** £0.9m adverse to plan. Under-performance linked to the under delivery against private patient/overseas income & CEA income removal.

**Pay:** £0.6m favourable to plan, driven by underspends across pay, primarily within nursing.

**Non Pay:** £2.9m favourable to Plan, driven by underspends across specialties due to overall reduced levels of activity. Activity levels higher in September resulting in increased non pay costs vs prior months and is primarily linked to Cardiology high cost devices

Total COVID costs YTD equate to £1.4m. Excluding these means a YTD position of £4m favourable to plan.

# CMG Financial Performance

## W&C

	Sep-20			YTD		
	Plan	Actual	Variance	Plan	Actual	Variance
	£'000	£'000	£'000	£'000	£'000	£'000
Patient Care Income	14,514	14,514	(0)	87,152	87,152	(0)
Non Patient Care Income	100	70	(30)	598	219	(378)
Other Operating Income	626	414	(211)	3,755	3,349	(406)
<b>Total Income</b>	<b>15,239</b>	<b>14,998</b>	<b>(241)</b>	<b>91,505</b>	<b>90,721</b>	<b>(784)</b>
Pay Costs	(7,853)	(8,020)	(167)	(47,390)	(47,674)	(284)
Pay Costs: Agency	(27)	(36)	(9)	(164)	(129)	35
Non Pay	(3,358)	(2,947)	412	(20,239)	(18,555)	1,683
<b>Total Operating Costs</b>	<b>(11,239)</b>	<b>(11,003)</b>	<b>236</b>	<b>(67,793)</b>	<b>(66,358)</b>	<b>1,435</b>
<b>Actual Surplus / (Deficit)</b>	<b>4,001</b>	<b>3,995</b>	<b>(5)</b>	<b>23,712</b>	<b>24,363</b>	<b>651</b>

## R&I

	Sep-20			YTD		
	Plan	Actual	Variance	Plan	Actual	Variance
	£'000	£'000	£'000	£'000	£'000	£'000
Patient Care Income	6	6	0	34	34	(0)
Non Patient Care Income	1	0	(1)	8	0	(8)
Other Operating Income	3,013	2,635	(377)	18,075	16,331	(1,745)
<b>Total Income</b>	<b>3,020</b>	<b>2,641</b>	<b>(379)</b>	<b>18,118</b>	<b>16,365</b>	<b>(1,753)</b>
Pay Costs	(1,349)	(1,314)	35	(8,092)	(7,872)	220
Pay Costs: Agency	0	0	0	0	(0)	(0)
Non Pay	(1,706)	(2,116)	(410)	(10,233)	(10,126)	108
<b>Total Operating Costs</b>	<b>(3,054)</b>	<b>(3,429)</b>	<b>(375)</b>	<b>(18,325)</b>	<b>(17,998)</b>	<b>327</b>
<b>Actual Surplus / (Deficit)</b>	<b>(35)</b>	<b>(788)</b>	<b>(754)</b>	<b>(207)</b>	<b>(1,633)</b>	<b>(1,426)</b>

## W&C

**Patient Care Income:** Daycase/ Elective Inpatient Activity £5.8m adverse, predominantly driven by activity under performance in all theatre areas.

Emergency/ Non-Elective £4.3m adverse.

Outpatients £3.9m adverse across all specialties.

Critical Care Services £3.0m adverse, linked to PICU at Glenfield being closed for April & May and reduced Paediatric HDU activity linked to reduced surgery activity. This is offset with the block related adjustment.

**Non Patient Care Income & Other Income:** £0.8m adverse due to lower private patient activity, and reduced maternity pathway charges and loss of baby scan income which has been offered free during Covid restrictions.

**Pay:** £0.2m adverse. Covid costs equate to £0.2m, largely within nursing.

**Non-Pay:** £1.7m favourable including Covid costs of £0.4m. Primarily in clinical supplies.

## R&I

There has been a one off adjustment in Month 6 to reverse out transactions to the balance sheet for Months 1 to 5 relating to Research Deposit Accounts. This resulted in an increased unplanned revenue expenditure of £522k. R&I has also incurred £225k of additional unfunded COVID-19 cost pressures this month.

**Income:** Reflects CMG expenditure patterns in month, low levels of commercial income and overheads and also reflects income lost through staff working on COVID. **Pay:** £35k in month favourable variance

**Non Pay:** £410k in month adverse variance. Reflects impact of £522k transfer from balance sheet. The underlying non pay cost versus budget is favourable.

# CMG Financial Performance

## Estates

	Sep-20			YTD		
	Plan	Actual	Variance	Plan	Actual	Variance
	£'000	£'000	£'000	£'000	£'000	£'000
Patient Care Income	0	0	0	0	0	0
Non Patient Care Income	0	0	0	0	1	1
Other Operating Income	1,835	1,270	(564)	11,007	6,936	(4,071)
<b>Total Income</b>	<b>1,835</b>	<b>1,270</b>	<b>(564)</b>	<b>11,007</b>	<b>6,937</b>	<b>(4,070)</b>
Pay Costs	(3,229)	(3,346)	(117)	(19,353)	(19,539)	(186)
Pay Costs: Agency	(6)	(50)	(44)	(38)	(634)	(597)
Non Pay	(3,289)	(3,220)	69	(19,736)	(18,813)	923
<b>Total Operating Costs</b>	<b>(6,524)</b>	<b>(6,616)</b>	<b>(92)</b>	<b>(39,126)</b>	<b>(38,986)</b>	<b>140</b>
<b>Actual Surplus / (Deficit)</b>	<b>(4,690)</b>	<b>(5,346)</b>	<b>(656)</b>	<b>(28,119)</b>	<b>(32,049)</b>	<b>(3,930)</b>

### Estates

**Income:** £4.1m adverse reflecting the loss of car parking £2.6m, catering £1.5m and shuttle bus income £57k due to Covid, partially mitigated by reduced non pay expenditure.

**Pay:** £0.8m adverse. Adjusting for Covid expenditure, the position would be £30k adverse.

**Non-Pay:** £0.9m favourable, inclusive of £2.2m Covid costs, representing a £0.1m increase on prior month costs. There are some savings on non-pay due to the reduced activity across the Trust, such as patient catering, laundry and postage.

## Corporate

	Sep-20			YTD		
	Plan	Actual	Variance	Plan	Actual	Variance
	£'000	£'000	£'000	£'000	£'000	£'000
Patient Care Income	0	0	0	0	0	0
Non Patient Care Income	0	0	(0)	0	0	(0)
Other Operating Income	579	551	(28)	3,476	3,061	(415)
<b>Total Income</b>	<b>579</b>	<b>551</b>	<b>(28)</b>	<b>3,476</b>	<b>3,061</b>	<b>(415)</b>
Pay Costs	(3,237)	(3,134)	103	(19,425)	(18,875)	550
Pay Costs: Agency	(18)	(49)	(30)	(110)	(218)	(108)
Non Pay	(3,947)	(3,947)	(0)	(23,680)	(23,898)	(219)
<b>Total Operating Costs</b>	<b>(7,202)</b>	<b>(7,130)</b>	<b>72</b>	<b>(43,215)</b>	<b>(42,992)</b>	<b>223</b>
<b>EBITDA</b>	<b>(6,623)</b>	<b>(6,579)</b>	<b>44</b>	<b>(39,739)</b>	<b>(39,931)</b>	<b>(192)</b>
<b>Non Operating Costs</b>	<b>0</b>	<b>(0)</b>	<b>(0)</b>	<b>0</b>	<b>(64)</b>	<b>(64)</b>
<b>Surplus / (Deficit)</b>	<b>(6,623)</b>	<b>(6,579)</b>	<b>43</b>	<b>(39,739)</b>	<b>(39,995)</b>	<b>(256)</b>

### Corporate

**Other Income:** £0.4m adverse reflecting the loss of training and Occupational Health income partially mitigated by reduction in non-pay.

**Pay:** £0.4m favourable to plan due to vacancies in Operations, Corporate Medical and Quality Strategy.

**Non Pay:** £0.3m adverse to plan. Overspends in Finance due to Kingsgate costs currently not included in the interim plan and COVID expenditure incurred in IM&T are mitigated by underspends in other Corporate areas.

# CMG Financial Performance

## Alliance

	Sep-20			YTD		
	Plan	Actual	Variance	Plan	Actual	Variance
	£'000	£'000	£'000	£'000	£'000	£'000
Patient Care Income	1,824	1,824	(0)	10,564	10,564	(0)
Non Patient Care Income	3	0	(3)	15	3	(13)
Other Operating Income	57	26	(31)	486	315	(171)
<b>Total Income</b>	<b>1,883</b>	<b>1,849</b>	<b>(34)</b>	<b>11,066</b>	<b>10,882</b>	<b>(184)</b>
Pay Costs	(1,089)	(1,004)	84	(6,536)	(5,866)	670
Pay Costs: Agency	(29)	(12)	18	(180)	(16)	164
Non Pay	(891)	(833)	57	(5,490)	(4,688)	802
<b>Total Operating Costs</b>	<b>(2,009)</b>	<b>(1,849)</b>	<b>160</b>	<b>(12,206)</b>	<b>(10,570)</b>	<b>1,636</b>
<b>Actual Surplus / (Deficit)</b>	<b>(126)</b>	<b>0</b>	<b>126</b>	<b>(1,140)</b>	<b>312</b>	<b>1,453</b>

I & E £'000

### Alliance

Day case activity continues to increase with 71 more cases than month 5, with Gastroenterology and Ophthalmology being the majority. YTD, there has been 2,344 day cases against a plan of 5,432 accounting for a £2.2m deficit.

Outpatients activity continues to increase and there was 1,010 more cases than month 5. A total of 6,572 outpatient attendances were recorded in September. The main areas of underperformance were Ophthalmology, Trauma and Orthopaedics and Gastroenterology. YTD, there has been an under delivery of 16,017 attendances accounting for a £3.9m deficit.

The block contract adjustment in respect of Covid-19 for September was £834k, £6.8m YTD.

**Pay:** A surplus of £20k is reported against the UHL Medical Staff SLA. Delivery against the SLA continues to improve as activity is restored and more clinics/sessions are delivered. £30k surplus in WLI spend and less reliance on external providers. The GPwSI pay budget is showing a £25k surplus as a result of a vacant post and a recharge of Urgent Care Centre sessions to CSI who account for the income.

**Non Pay:** Surpluses against consumable spend in line with reduced activity in day case and endoscopy are shown against the non-pay budget on various sites. Loughborough has reported a £12k surplus, Hinckley £13k and Melton £15k. £15k surplus is reported against the FP10 spend for September in line with reduced activity.

## Appendix 2: Pay Analysis

The table below shows a comparison of total Trust pay costs for the first six months of the financial year, compared to the same period in 2019/20 and 2018/19.

September 2020 expenditure include a correction for the Senior Medical Staff pay award.

	April £m	May £m	June £m	July £m	August £m	September £m
<b>2018/19 Pay</b>	<b>53.0</b>	<b>53.1</b>	<b>52.1</b>	<b>52.5</b>	<b>55.9</b>	<b>52.1</b>
<b>2019/20 Pay</b>	58.5	55.2	55.1	55.2	55.4	57.7
Medical Pay Award	0.3	0.3	0.3	0.3	0.3	(1.4)
<b>Revised 2019/20 Pay</b>	<b>58.8</b>	<b>55.5</b>	<b>55.4</b>	<b>55.4</b>	<b>55.7</b>	<b>56.3</b>
<b>2020/21 Pay</b>	<b>60.6</b>	<b>59.4</b>	<b>60.0</b>	<b>61.8</b>	<b>59.3</b>	<b>61.5</b>
<b>Increase / (Decrease) in underlying pay expenditure</b>	<b>1.8</b>	<b>3.9</b>	<b>4.6</b>	<b>6.4</b>	<b>3.5</b>	<b>5.2</b>
Inflation	1.7	1.7	1.7	1.7	1.7	1.7
Covid-19 expenditure	1.2	1.9	2.3	2.2	1.1	(0.2)
<b>Increase / (Decrease) in underlying pay expenditure</b>	<b>(1.1)</b>	<b>0.3</b>	<b>0.6</b>	<b>2.5</b>	<b>0.7</b>	<b>3.6</b>

## Appendix 3: WTE Analysis

The table below shows a comparison of total Trust WTE for the first six months of the financial year, compared to the same period in 2019/20 and 2018/19.

The increase in WTE's in August reflects the recruitment of temporary staff to support Covid-19.

		<b>April</b>	<b>May</b>	<b>June</b>	<b>July</b>	<b>August</b>	<b>September</b>
		<b>WTE</b>	<b>WTE</b>	<b>WTE</b>	<b>WTE</b>	<b>WTE</b>	<b>WTE</b>
<b>2018/19 Pay WTE</b>	<b>Total</b>	14,178.3	14,337.5	15,403.1	14,546.5	14,508.4	14,688.6
<b>2019/20 Pay WTE</b>	<b>Total</b>	14,352.2	14,435.9	14,521.5	14,509.1	14,627.4	14,845.3
<b>2020/21 Pay WTE</b>	<b>Total</b>	14,881.2	14,943.8	15,043.1	15,051.9	15,325.8	14,933.9
<b>Increase / (Decrease) in WTE</b>	<b>Total</b>	<b>529.0</b>	<b>507.8</b>	<b>521.6</b>	<b>542.7</b>	<b>698.4</b>	<b>88.6</b>